Stimulant, Antidepressant, and Opioid Telehealth Prescription Trends Between 2019 and 2022
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2024.33334 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Ashwini Nagappan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Fielding School of Public Health, UCLA, Los Angeles, California. Hauptthemen laut MEDLINE: Analgesics, Opioid, Telemedicine, Antidepressive Agents, Central Nervous System Stimulants. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Themen: Digitalisierung in der Pflege
Abstract (Originalsprache)
This cross-sectional study examines the rates of in-person and telehealth prescriptions for stimulants, antidepressants, and opioids before and during the COVID-19 pandemic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Policy and Management, Fielding School of Public Health, UCLA, Los Angeles, California.
- Trilliant Health, Brentwood, Tennessee.
- Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Förderung
- NCATS NIH HHS
Zitieren
APA
Nagappan, A., Miller, A., Jain, S., & Oakes, A. H. (2024). Stimulant, Antidepressant, and Opioid Telehealth Prescription Trends Between 2019 and 2022. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.33334
Vancouver
Nagappan A, Miller A, Jain S, Oakes AH. Stimulant, Antidepressant, and Opioid Telehealth Prescription Trends Between 2019 and 2022. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.33334
BibTeX
@article{Nagappan2024,
author = {Nagappan, Ashwini and Miller, Austin and Jain, Sanjula and Oakes, Allison H},
title = {Stimulant, Antidepressant, and Opioid Telehealth Prescription Trends Between 2019 and 2022},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2024.33334}
}
EUVIMED